The market capitalization of AIM stocks was £98.9bn as of 15th March 2023, down 4.3% since our update on the 27th of January 2023. Among the top YTD winners, there were Vast Resources (up 264% YTD, Mkt cap of £15.4m), Genedrive Plc (+236% YTD, MktCap £34.2mn), Celadon Pharmaceuticals (+177%, MktCap £86.3mn), Craven House Capital (+141%, £0.8mn), Genincode (+139%, MktCap £17.8mn), Inspecs Group (+138%, MktCap £104.2mn). Among the bottom movers, apart from canceling their admission to AIM compan ....

16 Mar 2023
LSE AIM Market Screener
10X Genomics Inc (TXG:NYSE), 0 | 10x Genomics Inc Class A (TXG:NAS), 0 | Jubilee Metals Group PLC (JLP:LON), 7.2 | Serabi Gold PLC (SRB:LON), 27.2 | Shanta Gold Limited (SHG:LON), 11.5
-
-
-
Marina Alekseenkova
-
10 pages
-

Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
LSE AIM Market Screener
10X Genomics Inc (TXG:NYSE), 0 | 10x Genomics Inc Class A (TXG:NAS), 0 | Jubilee Metals Group PLC (JLP:LON), 7.2 | Serabi Gold PLC (SRB:LON), 27.2 | Shanta Gold Limited (SHG:LON), 11.5
- Published:
16 Mar 2023 -
Author:
Marina Alekseenkova -
Pages:
10 -
The market capitalization of AIM stocks was £98.9bn as of 15th March 2023, down 4.3% since our update on the 27th of January 2023. Among the top YTD winners, there were Vast Resources (up 264% YTD, Mkt cap of £15.4m), Genedrive Plc (+236% YTD, MktCap £34.2mn), Celadon Pharmaceuticals (+177%, MktCap £86.3mn), Craven House Capital (+141%, £0.8mn), Genincode (+139%, MktCap £17.8mn), Inspecs Group (+138%, MktCap £104.2mn). Among the bottom movers, apart from canceling their admission to AIM compan ....